Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel purchased 2,000 shares of the business's stock in a transaction on Friday, December 9th. The stock was acquired at an average price of $13.11 per share, with a total value of $26,220.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,724,886 shares in the company, valued at approximately $35,723,255.46. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

• On Friday, December 2nd, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $13.84 per share, with a total value of $13,840.00.
• On Wednesday, November 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $8.79 per share, for a total transaction of $17,580.00.
• On Friday, October 14th, Snehal Patel acquired 3,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $9.75 per share, for a total transaction of $29,250.00.
• On Friday, October 7th, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $9.72 per share, with a total value of $19,440.00.
• On Friday, October 7th, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $9.72 per share, for a total transaction of $19,440.00.
• On Thursday, September 29th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $9.23 per share, for a total transaction of $9,230.00.

Greenwich LifeSciences Trading Up 0.8 %

Shares of NASDAQ GLSI opened at $13.13 on Thursday. The company has a market cap of $168.38 million, a P/E ratio of -23.03 and a beta of 0.81. Greenwich LifeSciences, Inc. has a 12-month low of $6.82 and a 12-month high of $30.79. The stock has a fifty day moving average price of $10.98 and a 200 day moving average price of $9.69.

Institutional Investors Weigh In On Greenwich LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GLSI. State Street Corp boosted its position in Greenwich LifeSciences by 1.8% in the 1st quarter. State Street Corp now owns 66,485 shares of the company's stock valued at $1,304,000 after buying an additional 1,176 shares during the last quarter. Bank of America Corp DE grew its position in shares of Greenwich LifeSciences by 100.2% during the first quarter. Bank of America Corp DE now owns 6,213 shares of the company's stock worth $122,000 after buying an additional 3,110 shares in the last quarter. Walleye Capital LLC acquired a new position in Greenwich LifeSciences in the second quarter worth about $90,000. Goldman Sachs Group Inc. bought a new stake in Greenwich LifeSciences in the second quarter valued at about $104,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Greenwich LifeSciences during the second quarter valued at approximately $130,000. Hedge funds and other institutional investors own 8.06% of the company's stock.

About Greenwich LifeSciences

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

See Also

• Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
• Is Enterprise Products Partners Fairly Valued?
• Will WhatsApp Partnership Boost MercadoLibre's Earnings?
• 3 Mid-Caps That Could Double in 2023
• Mullen Automotive Shares Jump After Signing New Partner
• REV Group Leads Specialty Vehicle Manufacturers Higher

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.